Get ready for more merger mania in pharma sector the rest of the year
Pfizer Buys Global Blood Therapeutics. How the Deal Could Solve Pipeline Worries.
Why Pfizer (PFE) Is Buying Global Blood Therapeutics (GBT) For $5.4 Billion
Pfizer reaches $5.4B deal for Global Blood Therapeutics
Pfizer confirms to acquire Global Blood Therapeutics for $5.4 billion in deal that gives it access to sickle-cell disease treatment
Pfizer to buy Global Blood Therapeutics in $5.4 billion deal
Pfizer agrees to buy Global Blood Therapeutics in deal valued at $5.4 billion: WSJ
Pfizer in Talks to Buy Global Blood Therapeutics: Report
WSJ: Pfizer considering buying Global Blood Therapeutics for roughly $5 billion
Pfizer in advanced talks to buy Global Blood Therapeutics for $5 billion - WSJ
Global Blood Therapeutics shares jump 34% after Bloomberg report about 'takeover interest'
5 Top Biotech Stocks To Watch In July 2022
Global Blood Therapeutics' Oxbryta Scores European Approval For Sickle Cell Disease